8. ハンチントン病 Huntington disease Clinical trials / Disease details
臨床試験数 : 229 / 薬物数 : 193 - (DrugBank : 60) / 標的遺伝子数 : 84 - 標的パスウェイ数 : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-000904-24-NL (EUCTR) | 15/02/2016 | 17/02/2016 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Germany;Netherlands;Italy;United Kingdom | ||
| 2 | EUCTR2015-000904-24-DE (EUCTR) | 03/12/2015 | 04/08/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Poland;Austria;Australia;France;United States;Canada;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 3 | EUCTR2015-000904-24-AT (EUCTR) | 18/11/2015 | 15/09/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 19.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;United States;Canada;Poland;Denmark;Australia;Austria;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 4 | EUCTR2015-000904-24-GB (EUCTR) | 13/11/2015 | 18/08/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;United States;Canada;Poland;Austria;Australia;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 5 | EUCTR2015-000904-24-IT (EUCTR) | 15/09/2015 | 23/02/2018 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington's Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidina Product Code: TV-7820 INN or Proposed INN: Pridopidina Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidina Product Code: TV-7820 INN or Proposed INN: Pridopidina Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Italy | ||
| 6 | EUCTR2013-001888-23-DK (EUCTR) | 13/04/2015 | 08/01/2015 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Denmark;Australia;Germany;Netherlands | ||
| 7 | EUCTR2013-001888-23-PL (EUCTR) | 23/07/2014 | 14/05/2014 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 8 | EUCTR2013-001888-23-AT (EUCTR) | 01/07/2014 | 08/01/2014 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 9 | EUCTR2013-001888-23-NL (EUCTR) | 07/04/2014 | 20/12/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Netherlands;Germany | ||
| 10 | EUCTR2013-001888-23-DE (EUCTR) | 25/03/2014 | 10/12/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 11 | EUCTR2013-001888-23-IT (EUCTR) | 13/03/2014 | 11/12/2013 | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | Netherlands;United States;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany | ||
| 12 | EUCTR2013-001888-23-GB (EUCTR) | 22/01/2014 | 27/11/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 13 | NCT01306929 (ClinicalTrials.gov) | March 1, 2011 | 28/2/2011 | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease | A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART). | Huntington Disease | Drug: pridopidine | Prilenia | NULL | Completed | N/A | N/A | All | 235 | Phase 2 | United States;Canada |
| 14 | EUCTR2007-004988-22-AT (EUCTR) | 02/04/2009 | 19/02/2008 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 15 | NCT00724048 (ClinicalTrials.gov) | October 2008 | 24/7/2008 | A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease | A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART) | Huntington Disease | Drug: ACR16 10 mg;Drug: ACR16 22.5 mg;Drug: ACR16 45 mg;Other: Placebo | Teva Pharmaceutical Industries | NULL | Completed | 30 Years | N/A | Both | 227 | Phase 2/Phase 3 | United States;Canada |
| 16 | EUCTR2007-004988-22-IT (EUCTR) | 26/08/2008 | 29/07/2008 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington?s Disease - ND | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington?s Disease - ND | Huntington's Disease | Product Code: ACR16 | NEUROSEARCH SWEDEN AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 17 | EUCTR2007-004988-22-PT (EUCTR) | 06/06/2008 | 14/02/2008 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Austria;Italy;Spain;France;Belgium;United Kingdom;Germany;Portugal | |||
| 18 | EUCTR2007-004988-22-ES (EUCTR) | 03/06/2008 | 11/02/2008 | Un estudio multicentro, internacional, aleatorizado, doble ciego y de grupos paralelos que compara la administración de ACR16 45 mg una o dos veces al día frente al placebo, para el tratamiento sintomático de la Enfermedad de Huntington.(A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease) - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Un estudio multicentro, internacional, aleatorizado, doble ciego y de grupos paralelos que compara la administración de ACR16 45 mg una o dos veces al día frente al placebo, para el tratamiento sintomático de la Enfermedad de Huntington.(A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease) - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Enfermedad de Huntington (Huntington's Disease) MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 19 | EUCTR2007-004988-22-FR (EUCTR) | 23/05/2008 | 08/01/2008 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 20 | NCT00665223 (ClinicalTrials.gov) | April 2008 | 22/4/2008 | A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease | A Multicentre, Multinational, Randomized, Double-blind, Parallel-group Study Comparing ACR16 Versus Placebo for the Symptomatic Treatment of Huntington's Disease | Huntington's Disease | Drug: ACR16;Drug: Placebo | Teva Pharmaceutical Industries | NULL | Completed | 30 Years | N/A | Both | 437 | Phase 3 | Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom |
| 21 | EUCTR2007-004988-22-DE (EUCTR) | 22/02/2008 | 26/10/2007 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;France;Spain;Belgium;Austria;Germany;Italy;United Kingdom | |||
| 22 | EUCTR2007-004988-22-GB (EUCTR) | 11/01/2008 | 16/10/2007 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 23 | EUCTR2007-004988-22-BE (EUCTR) | 04/01/2008 | 30/10/2007 | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) | Huntington's Disease MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: ACR16 Product Code: ACR16 | NeuroSearch Sweden AB | NULL | Not Recruiting | Female: yes Male: yes | 420 | Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria | |||
| 24 | EUCTR2004-000394-60-DK (EUCTR) | 05/10/2004 | 17/08/2004 | A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CNS, depending on the initial level of dopaminergic activity. The stabilizing feature of such compounds is illustrated by their interaction with dopaminergic agonists. | Product Name: ACR16 Product Code: ACR16 | A. Carlsson Research AB | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Denmark;Sweden | ||
| 25 | EUCTR2004-000394-60-SE (EUCTR) | 30/06/2004 | 13/05/2004 | A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CNS, depending on the initial level of dopaminergic activity. The stabilizing feature of such compounds is illustrated by their interaction with dopaminergic agonists. | Product Name: ACR16 Product Code: ACR16 | A. Carlsson Research AB | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Denmark;Sweden |